Enzootik pnömonili buzağılarda parapoxvirus ovis D1701 suşu ve enrofloxacin kombinasyonunun tedavi etkinliği üzerinde bir araştırma

A study concerning the therapeutic effectiveness of the enrofloxacin and parapoxvirus D1701 combination in calves with enzootic pneumonia

Özet

Ruminantlarm solunum yolu infeksiyonlarmda sıkça kullanılan bir antibiotik olan Enrofloxacin ile bir immunomodulator olan Parapoxvirus D1701 susu kombinasyonun enzootik pnömoli danalardaki tedavi etkinliği araştırıldı. Bu amaçla 15 enzootik pnömonili danalar iki gruba ayrıldı, ilk grub (n=7) Enrofloxacin ve Parapoxvirus D1701 kombinasyon tedavisi, diğer gruba (n=8) ise sadece Enrofloxacin tedavisi uygulandı. Kombinasyon uygulanan grupta tedavinin 3. gününde klinik iyileşme oranı %74 iken, yalnız Enrofoxacin uygulanan grupta bu oran %25 olarak bulunmuştur. Her iki grupta da tedavi esnasında ölen hayvan olmamıştır. Sonuç olarak, enzootik pnömonili buzağıların tedavisinde Enrofloxacin'e Parapoxvirus D1701 eklenmesinin, sadece Enrofloxacin uygulanmasına göre tedavi etkiniğini arttırdığı sonucuna varılmıştır.

Abstract

Therapeutic effectiveness of the combination therapy with Enrofloxacin, an antibiotic which was used frequently in the respiratory diseases of ruminants and Parapoxvirus D1701 that is an immunomodulator were investigated in calves with enzootic pneumonia. For that reason, 15 calves with enzootic pneumonia were divided two groups; first group (n=7) which was treated with Enrofloxacin and Parapoxvirus D1701 combination, and second group (n=8) which was treated only with Enrofloxacin, respectively. At the third day of the treatment, cure rate was 74% in group which was treated with combination therapy, and 25% in group which was treated with monotherapy. No death was detected in both groups. As a result, we conclude that combination of Parapoxvirus with Enrofloxacine resulted in more effective therapy than the Enrofloxacine monotheraphy in the treatment of calves with enzootic pneumoniae.